Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer

HUNG-YANG KUOJHE-CYUAN GUOCHIH-HUNG HSU2022-11-072022-11-072023-01-060929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/624476en[SDGs]SDG3Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancerjournal article10.1016/j.jfma.2022.05.009356804712-s2.0-85131437236https://scholars.lib.ntu.edu.tw/handle/123456789/617263